Evidence map›Paper›PMID 25118659›Full record

ArticleMolecular medicine reports2014

1‑calcium phosphate‑uracil, a synthesized pyrimidine derivative agent, has anti‑proliferative, pro‑apoptotic and anti‑invasion effects on multiple tumor cell lines.

Jing Peng, Xinlian Chen, Qian Hu, Mei Yang, Hongqian Liu, Wei Wei, Shanling Liu, He Wang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jing PengLaboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Xinlian ChenLaboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Qian HuLaboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Mei YangLaboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Hongqian LiuLaboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Wei WeiLaboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Shanling LiuLaboratory of Cell and Gene Therapy, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
He WangLaboratory of Genetics, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Sichuan University · CNWest China Second University Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1‑calcium phosphate‑uracil (1‑CP‑U), a synthetic pyrimidine derivative, has been documented to demonstrate a variety of different biological activities. However, the potency and mechanisms of this agent's anti-cancer activity have not been elucidated to date. In the present study, the anti‑cancer effects of 1‑CP‑U were examined in a range of in vitro assays. Different cell lines were treated with 1‑CP‑U at varied concentrations (0.7, 1.0, 1.4 µmol/l) for indicated durations. The cell proliferation was then examined by MTT assay. The cellular apoptotic effects were detected by Hoechst 33342 and Annexin V/propidium iodide staining, while the capacity of 1‑CP‑U on invasion and migration were examined by cell invasion and wound healing assays. The expression of matrix metalloproteinase proteins, as well as pro‑ and antiapoptotic proteins was detected by western blotting analysis. The results identified that 1‑CP‑U was able to inhibit the viability of SKOV3, HeLa, SMMC‑7721 and A549 cell lines in a dose‑ and time‑dependent manner, while it exerted only marginal toxic effects on non‑cancerous cells. The IC50 concentration of 1‑CP‑U for tumor cell lines was ~1.0 µmol/l. The growth inhibition induced by 1‑CP‑U was accompanied by a broad spectrum of pro‑apoptotic activities, in which different cell lines varied in their sensitivity to 1‑CP‑U. Meanwhile, the increased expression of the pro‑apoptotic protein B-cell lymphoma-2 (Bcl-2)-associated X and a marked reduction of Bcl‑2 levels were associated with increased 1‑CP‑U concentrations. Additionally, anti‑migration and anti‑invasion effects of 1‑CP‑U were evidently associated with the downregulation of matrix metalloproteinase proteins. Of note, it was observed that 1‑CP‑U significantly inhibited both the migration and invasion at a lower concentration, as compared with the dose required to achieve significant inhibition of apoptosis. These results indicated that 1‑CP‑U appeared to be a more effective inhibitor of cell migration and invasion, rather than of apoptosis. In conclusion, the present study was the first, to the best of our knowledge, to demonstrate the function of 1‑CP‑U in tumor proliferation, apoptosis and invasion with specific effects against cancer cells in vitro, suggesting 1‑CP‑U as a potential novel anticancer agent.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell MovementCell ProliferationDrug Screening Assays, AntitumorHumansMatrix Metalloproteinase 2Neoplasm InvasivenessOrganophosphorus CompoundsUracil1-calcium phosphate-uracilAntineoplastic AgentsMatrix Metalloproteinase 2MMP2 protein, humanOrganophosphorus CompoundsUracil

Identifiers

PMID25118659
PMCPMC4214340
OpenAlexW1983685483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.